Research Interests
Breast Cancer
Triple Negative Breast Cancer
Brain Metastases
Young women and Breast Cancer
Triple Negative Breast Cancer
Brain Metastases
Young women and Breast Cancer
Selected Grants
Phase 2 Study of Zelenectide Pevedotin in Participants with NECTIN4 Amplified Advanced Breast Cancer
Clinical TrialPrincipal Investigator · Awarded by BicycleTx Limited · 2025 - 2030Prospective Registry of Trastuzumab Deruxtecan in Patients with Active/Progressive HER2-Positive Breast Cancer Brain Metastases
ResearchPrincipal Investigator · Awarded by Johns Hopkins University · 2025 - 2030DATO-BASE: A phase 2 trial of DATOpotamab-deruxtecan for breast cancer Brain metAstaSEs
Clinical TrialPrincipal Investigator · Awarded by Dana-Farber Cancer Institute · 2024 - 2029BGB-43395-101 (CDK-4) - A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of the CDK4 Inhibitor BGB-43395
Clinical TrialPrincipal Investigator · Awarded by BeiGene USA, Inc. · 2024 - 2029A single shot therapy will accelerate the elimination of breast cancer
ResearchCo Investigator · Awarded by United States Army Medical Research Acquisition Activity · 2024 - 2028Identifying and exploiting therapeutic vulnerabilities of tumor-host interactions that drive bone-to-meninges breast cancer metastasis
ResearchConsultant · Awarded by National Institutes of Health · 2023 - 2028Incyclix INX-315-01
Clinical TrialPrincipal Investigator · Awarded by Incyclix Bio, LLC · 2023 - 2028Determining susceptibility loci in triple negative breast cancer using a novel pre-clinical model
ResearchPrincipal Investigator · Awarded by University of Tennessee Health Science Center · 2022 - 2027Phase I/II Study of Stereotactic Radiosurgery with Concurrent Administration of DNA Damage Response (DDR) Inhibitor (Olaparib) Followed by Adjuvant Combination of Durvalumab (MEDI4736) and Physicians
Clinical TrialPrincipal Investigator · Awarded by Hoosier Cancer Research Network, Inc · 2022 - 2027A Prospective Registry for Patients with Metastatic Breast Cancer and Leptomeningeal Metastases
ResearchPrincipal Investigator · Awarded by Dana-Farber Cancer Institute · 2025 - 2026A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of ZN-A-1041 Enteric Capsules as a Single Agent or in Combination with Capecitabine Tablets in Patients with HER2-Positive Advanced Solid Tumors
Clinical TrialPrincipal Investigator · Awarded by Suzhou Zanrong Pharma Limited · 2020 - 2026Ancestry-related RNA splicing and immune expression in metastatic breast cancer
ResearchCo Investigator · Awarded by Susan G. Komen Breast Cancer Foundation · 2022 - 2026Breast Cancer Brain Metastases: Integrating Immunogenomic and Phenotypic Vulnerabilities to Improve Outcomes
ResearchPrincipal Investigator · Awarded by Department of Defense · 2025 - 2026ABL-regulated transcriptional and epigenetic networks promote outgrowth of breast cancer metastases revealing novel therapeutic targets
ResearchPrincipal Investigator · Awarded by Department of Defense · 2022 - 2025ABL-regulated transcriptional and epigenetic networks promote outgrowth of breast cancer metastases revealing novel therapeutic targets
ResearchPartnering PI · Awarded by Department of Defense · 2022 - 2025R01 Defining and targeting a novel pathway for central nervous system leptomeningeal metastasis
ResearchCollaborator · Awarded by National Cancer Institute · 2020 - 2025A TWO-PART, PHASE 1A/B, OPEN-LABEL, MULTICENTER TRIAL EVALUATING PHARMACOKINETICS, SAFETY AND EFFICACY OF PF-07284890 (ARRY-461) IN PARTICIPANTS WITH BRAF V600-MUTANT SOLID TUMORS WITH AND WITHOUT BRAIN INVOLVEMENT
Clinical TrialPrincipal Investigator · Awarded by Pfizer, Inc. · 2020 - 2025Aurora US: Prospective Biospecimen Repository in Metastatic Breast Cancer
ResearchPrincipal Investigator · Awarded by Johns Hopkins University · 2024 - 2025Dose Escalation and Expansion Clinical Study to Evaluate the Safety and Efficacy of ELU001 in Subjects who have advanced, recurrent or refractory FRa overexpressing tumors
Clinical TrialPrincipal Investigator · Awarded by Elucida Oncology, Inc · 2022 - 2025Translational Breast Cancer Research Consortium 2024 Infrastructure - SGK
Clinical TrialPrincipal Investigator · Awarded by Johns Hopkins University · 2024 - 2025Translational Breast Cancer Research Consortium 2024 Infrastructure (BCRF)
Clinical TrialPrincipal Investigator · Awarded by Johns Hopkins University · 2024 - 2025An Open-Label, Multinational, Multicenter, Phase 3b/4 Study of Trastuzumab Deruxtecan in Patients With or Without Baseline Brain Metastasis With Previously Treated Advanced/Metastatic HER2 Positive Br
Clinical TrialPrincipal Investigator · Awarded by AstraZeneca Pharmaceuticals, LP · 2021 - 2025Retrospective tissue study HER2-positive breast cancer prediction of brain metastasis
ResearchPrincipal Investigator · Awarded by Caris Life Sciences · 2021 - 2025A Randomized Open-Label, Multi-Center Pivotal Study of ANG1005 Compared with Physician's Best Choice in HER2-Negative Breast Cancer Patients with Newly Diagnosed Leptomeningeal Carcinomatosis and Previously Treated Brain Metastases (ANGLeD)
Clinical TrialPrincipal Investigator · Awarded by Angiochem Inc. · 2019 - 2024A Phase 1b/2 Multicentre, Open-label, Modular, Dose-finding and Dose-expansion Study to Explore the Safety, Tolerability, and Anti-tumour Activity of Trastuzumab Deruxtecan (T-DXd) in Combination with other Anti-cancer Agents in Patients with HER2-p
Clinical TrialPrincipal Investigator · Awarded by AstraZeneca Pharmaceuticals, LP · 2022 - 2023Defining Optimal Radiotherapy Dose and Fractionation in Combination with Preoperative Immuno-Chemotherapy in Early-Stage Triple Negative Breast Cancer
ResearchCo Investigator · Awarded by National Institutes of Health · 2023 - 2023Dr. Anders-Cancer Research
ResearchPrincipal Investigator · Awarded by 5 for the Fight · 2022 - 2022T32 UNC - Duke Immunotherapy Training Program
Inst. Training Prgm or CMEPreceptor · Awarded by University of North Carolina - Chapel Hill · 2021 - 2022In Vitro Fertilization Outcomes in Women Diagnosed with Cancer
ResearchPrincipal Investigator · Awarded by University of North Carolina - Chapel Hill · 2020 - 2022Discovery and validation of putative oncogenic ROS1 alterations in metastatic breast cancer
ResearchMentor · Awarded by Metavivor · 2020 - 2022Immunotherapy to treat Triple Negative Breast Cancer Brain Metastases
ResearchPrincipal Investigator · Awarded by University of North Carolina - Chapel Hill · 2019 - 2021Molecular Dissection and Immune Characterization of Breast Cancer Brain Metastases to Predict Outcomes and Reveal Novel Therapeutic Strategies
ResearchPrincipal Investigator · Awarded by Conquer Cancer Foundation · 2019 - 2019External Relationships
- ASCO
- AstraZeneca
- Beigene
- Curio Healthcare
- Daiichi Sankyo Co., Ltd
- Elucida Oncology, Inc
- Johnson and Johnson
- Jones Bartlett Learning (publishers)
- Novartis
- OncLive
- Physician Education Resource
- Roche
- UpToDate, Inc
- WebMD/Medscape
This faculty member (or a member of their immediate family) has reported outside activities with the companies, institutions, or organizations listed above. This information is available to institutional leadership and, when appropriate, management plans are in place to address potential conflicts of interest.